First-line immunochemotherapy for advanced NSCLC in Asian patients: a meta-analysis of phase 3 RCTs.

ABSTRACT:

Background

PD-1/PD-L1 inhibitors plus chemotherapy (PC) are now broadly acknowledged as effective for treating stage IIIb-IV non-small cell lung cancer (NSCLC). However, data specific to Asian populations remain limited, and updated evidence from randomized controlled trials (RCTs) is warranted. In this study, the efficacy and safety of PC are analyzed and compared with those of chemotherapy in this population.

Methods

Six databases were systematically explored to locate applicable phase 3 RCTs. Eligible studies involved Asian patients with stage IIIb-IV NSCLC and compared PC treatment with conventional chemotherapy. Overall survival (OS) and progression-free survival (PFS) were regarded as primary endpoints.

Results

A total of 16 phase 3 RCTs involving 4,452 Asian pa

SUBMITTER: Mao Z 

PROVIDER: S-EPMC12672283 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature